The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.
A Molecularly Annotated Platform of Patient-Derived Xenografts (“Xenopatients”) Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
Open accessPublished version of a preprint
Abstract
Only a fraction of patients with metastatic colorectal cancer receive clinical benefit from therapy with anti-epidermal growth factor receptor (EGFR) antibodies, which calls for the identification of novel biomarkers for better personalized medicine. We produced large xenograft cohorts from 85 patient-derived, genetically characterized metastatic colorectal cancer samples (“xenopatients”) to discover novel determinants of therapeutic response and new oncoprotein targets. Serially passaged tumors retained the morphologic and genomic features of their original counterparts. A validation trial confirmed the robustness of this approach: xenopatients responded to the anti-EGFR antibody cetuximab with rates and extents analogous to those observed in the clinic and could be prospectively stratified as responders or nonresponders on the basis of several predictive biomarkers. Genotype–response correlations indicated HER2 amplification specifically in a subset of cetuximab-resistant, KRAS/NRAS/BRAF/PIK3CA wild-type cases. Importantly, HER2 amplification was also enriched in clinically nonresponsive KRAS wild-type patients. A proof-of-concept, multiarm study in HER2-amplified xenopatients revealed that the combined inhibition of HER2 and EGFR induced overt, long-lasting tumor regression. Our results suggest promising therapeutic opportunities in cetuximab-resistant patients with metastatic colorectal cancer, whose medical treatment in the chemorefractory setting remains an unmet clinical need. Significance: Direct transfer xenografts of tumor surgical specimens conserve the interindividual diversity and the genetic heterogeneity typical of the tumors of origin, combining the flexibility of preclinical analysis with the informative value of population-based studies. Our suite of patient-derived xenografts from metastatic colorectal carcinomas reliably mimicked disease response in humans, prospectively recapitulated biomarker-based case stratification, and identified HER2 as a predictor of resistance to anti-epidermal growth factor receptor antibodies and of response to combination therapies against HER2 and epidermal growth factor receptor in this tumor setting. Cancer Discovery; 1(6); 508–23. ©2011 AACR. Read the Commentary on this article by Ciardiello and Normanno, p. 472 This article is highlighted in the In This Issue feature, p. 457
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HER2 overexpression is a negative predictor associated with reduced efficacy of anti-EGFR therapy [31], and >36% of cetuximab-resistant mCRC with wild-type KRAS, NRAS, BRAF, and PI3K was found to display HER2 overexpression [32].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [32]
In the citing paper
“A series of studies have demonstrated that HER2 gene amplification or activating mutations can mediate resistance to anti-EGFR mAbs in CRC [27,178,179].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Preclinical studies have shown that the combination of HER2 and EGFR blockade can lead to CRC tumor regression [27,28,29].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [27]
In the citing paper
“Two independent studies have recently shown that HER2 amplification is a predictor of poor sensitivity to anti-EGFR antibodies [91, 92].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“In retrospective studies, patients with tumors featuring HER2 amplification or heregulin overexpression and treated with cetuximab or panitumumab experienced disease progression and shorter progression-free and overall survival compared with HER2 wild-type cases [91-93].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“only the dual targeting of HER2 and EGFR by combining a small-molecule inhibitor, such as the dual EGFR/HER2 inhibitor lapatinib, with a moAb, such as cetuximab or pertuzumab, induced overt and long-lasting tumor regressions in proof-of-concept trials in HER2-amplified xenopatients [91].”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Increased EGFR gene copy number could predict response among KRAS wild-type patients [53, 91, 111-113]”
From Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies (2014) · cites this paper as [91]
In the citing paper
“Strong preclinical evidence suggests that dual inhibition of ERBB2 is superior to monotherapy due to enhanced efficacy and reduced therapy resistance4648”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [46]
In the citing paper
“Bertotti et al. identified ERBB2 as a biomarker of resistance to anti-EGFR mAbs [113].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“A total of 2–7% of unselected CRCs were found to have ERBB2/mutations, and this number was much higher in KRAS wild-type cases (13.6%) and in KRAS/NRAS/BRAF/PIK3CA quadruple wild-type cases (36% )[13, 113, 114].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [113]
In the citing paper
“Finally, using patient-derived colon cancer xenografts, Bertotti et al. identified HER2 gene amplification as a predictor of resistance to cetuximab among KRAS wild-type tumors (Bertotti et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Bertotti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationUmar, A., Boland, C. R., Terdiman, J. P., Syngal, S., de la Chapelle, A., Rüschoff, J., Fishel, R. A., Lindor, N. M., Burgart, L. J., Hamelin, R., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh034 · Cited by 3,181
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
De Roock, W., Claes, B., Bernasconi, D., De Schutter, J., Biesmans, B., Fountzilas, G., Kalogeras, K. T., Kotoula, V., Papamichael, D., Laurent-Puig, P., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70130-3 · Cited by 2,144
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cited by
Sorted by citations
Items 601–700 of 944
Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
Torres-Jiménez, J., Esteban-Villarrubia, J., & Ferreiro, R. (2022) · Cancers · doi:10.3390/cancers14153718 · Cited by 11
Ciardiello, D., Napolitano, S., Famiglietti, V., Esposito, L., Falco, V. D., Liello, A. D., Avallone, A., Maiello, E., Pietrantonio, F., Cremolini, C., et al. (2023) · Cancers · doi:10.3390/cancers15072117 · Cited by 11
Caiazza, F., Elliott, L., Fennelly, D. W., Sheahan, K. D., Doherty, G. A., & Ryan, E. J. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.5 · Cited by 13
Valtorta, S., Moro, M., Prisinzano, G., Bertolini, G., Tortoreto, M., Raccagni, I., Pastorino, U., Roz, L., Sozzi, G., & Moresco, R. M. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.176404 · Cited by 11
Sefrioui, D., Vermeulin, T., Blanchard, F., Chapusot, C., Beaussire, L., Armengol‐Debeir, L., Sesboüé, R., Gangloff, A., Hebbar, M., Copin, M., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30584 · Cited by 13
A Road Map for Precision Cancer Medicine Using Personalized Models
Picco, G., & Garnett, M. J. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0268 · Cited by 11
Patient-Derived Xenograft Models of Colorectal Cancer: Procedures for Engraftment and Propagation
Burgenske, D. M., Monsma, D. J., & MacKeigan, J. P. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7765-9_20 · Cited by 11
Yang, M., Fang, X., Li, J., Xu, D., Xiao, Q., Yu, S., Hu, H., Weng, S., Ding, K., & Yuan, Y. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1529120 · Cited by 11
Wimsatt, J., Montgomery, C., Thomas, L. S., Savard, C., Tallman, R. M., Innes, K. E., & Jrebi, N. Y. (2018) · PeerJ · doi:10.7717/peerj.5602 · Cited by 11
Fuentes, N. R., Mlih, M., Wang, X., Webster, G., Cortes-Acosta, S., Salinas, M. L., Corbin, I. R., Karpac, J., & Chapkin, R. S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100026 · Cited by 11
Rossanese, O. W., Eccles, S. A., Springer, C. J., Swain, A., Raynaud, F. I., Workman, P., & Kirkin, V. (2016) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2017.07.002 · Cited by 11
Raghav, K. P. S., Guthrie, K. A., Tan, B. R., Denlinger, C. S., Fakih, M., Overman, M. J., Dasari, A. N., Corum, L. R., Hicks, L. G., Patel, M. D., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01710 · Cited by 12
Sheng, Y., Xie, Z., Wang, J., Yang, X., Yao, M., Qian, W., Zhang, L., Chen, X., & Guo, S. J. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0008 · Cited by 10
Heterogeneity and evolution of DNA mutation rates in microsatellite stable colorectal cancer
Grassi, E., Vurchio, V., Cresswell, G. D., Catalano, I., Lupo, B., Sassi, F. P., Galimi, F., Borgato, S., Ferri, M., Viviani, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.ado1641 · Cited by 11
Self-citationKOVALCHUK, A. V., Ilnytskyy, Y., Rodriguez‐Juarez, R., Shpyleva, S., Melnyk, S., Pogribny, I. P., Katz, A. M., Sidransky, D., Kovalchuk, O., & Kolb, B. E. (2017) · Aging · doi:10.18632/aging.101243 · Cited by 10
Ohkuma, R., Yada, E., Ishikawa, S., Komura, D., Kubota, Y., Hamada, K., Horiike, A., Ishiguro, T., Hirasawa, Y., Ariizumi, H., et al. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5147 · Cited by 10
Lafferty, A., O’Farrell, A. C., Migliardi, G., Khemka, N., Lindner, A. U., Sassi, F. P., Zanella, E. R., Salvucci, M., Vanderheyden, E., Modave, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0818 · Cited by 10
Self-citationXin, Y., Jiang, Q., Liu, C., & Qiu, J. (2023) · Aging · doi:10.18632/aging.205175 · Cited by 10
Hanna, D. L., & Lenz, H. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1172961 · Cited by 10
The State of the Art in Colorectal Cancer Molecular Biomarker Testing
Pillai, R. K., Lopategui, J. R., Dhall, D., Guindi, M. M., Slavin, T. P., Lofton–Day, C., & Patterson, S. D. (2016) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000107 · Cited by 10
Gelfo, V., Pontis, F., Mazzeschi, M., Sgarzi, M., Mazzarini, M., Solmi, R., D'Uva, G., & Lauriola, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050600 · Cited by 9
Patient-derived xenograft models for personalized medicine in colorectal cancer
Xie, J., & Lin, Y. (2020) · Clinical and Experimental Medicine · doi:10.1007/s10238-020-00609-4 · Cited by 12
Fu, D., Li, C., & Huang, Y. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s286813 · Cited by 10
Endometrial Cancer Patient-Derived Xenograft Models: A Systematic Review
Tanaka, T., Nishie, R., Ueda, S., Miyamoto, S., Hashida, S., Konishi, H., Terada, S., Kogata, Y., Sasaki, H., Tsunetoh, S., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092606 · Cited by 9
Benvenuti, S., Gentile, A., Lazzari, L., Arnesano, A., Trusolino, L., & Comoglio, P. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.006 · Cited by 10
Self-citationYeh, Y., Lee, C., Chen, S., Lee, C., Chen, Y., Lin, B.-W., Lin, S.-C., Chan, R., Lee, J., Shen, M.-R., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s213247 · Cited by 11
Rajaram, S., Roth, M. A., Malato, J., VandenBerg, S. R., Hann, B. C., Atreya, C. E., Altschuler, S. J., & Wu, L. F. (2019) · Scientific Data · doi:10.1038/s41597-019-0225-0 · Cited by 10
Némati, F., de Koning, L., Gentien, D., Assayag, F., Henry, E., Raïs, K. A., Pierron, G., Mariani, O., Nijnikoff, M., Champenois, G., et al. (2023) · Current Oncology · doi:10.3390/curroncol30100657 · Cited by 9
Suzuki, T., Henshaw, M. J., Yanagi, T., & Aoshima, K. (2023) · Research in Veterinary Science · doi:10.1016/j.rvsc.2023.105120 · Cited by 8
Intrinsic Epigenetic State of Primary Osteosarcoma Drives Metastasis
Singh, I., Rainusso, N. C., Kurenbekova, L., Nirala, B. K., Dou, J., Muruganandham, A., & Yustein, J. T. (2024) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-23-0055 · Cited by 9
Menéndez, J. A. (2012) · Oncology Reports · doi:10.3892/or.2012.1732 · Cited by 9
Kılıçarslan, A., Doğan, H. T., Süngü, N., Doğan, M., Yalçin, S., & Dede, D. Ş. (2018) · Polish Journal of Pathology · doi:10.5114/pjp.2018.75671 · Cited by 9
Tucatinib: an investigational novel therapeutic agent for the treatment of HER-2 colorectal cancer
Ahn, D. H., Walden, D. M., & Bekaii‐Saab, T. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2053107 · Cited by 9
Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI
Volovăț, S. R., Augustin, I. G., Zob, D., Boboc, D., Amurariti, F., Volovat, C. D., Ştefănescu, C., Stolniceanu, C. R., Ciocoiu, M., Dumitras, E. A., et al. (2022) · Cancers · doi:10.3390/cancers14194834 · Cited by 10
Optimizing Drug Response Study Design in Patient-Derived Tumor Xenografts
Weiss, J., Pham, N., Pintilie, M., Li, M., Liu, G., Shepherd, F. A., Tsao, M., & Xu, W. (2022) · Cancer Informatics · doi:10.1177/11769351221136056 · Cited by 9
Dazio, G., Epistolio, S., Frattini, M., & Saletti, P. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247523 · Cited by 10
Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2
Dao, V. A., & Heestand, G. M. (2023) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2023.100960 · Cited by 9
Zhou, H., Lv, M., Li, W., Wang, Y., Wu, J., Liu, Q., Liu, T., Cui, Y., & Li, Q. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.10.008 · Cited by 10
Zhao, Y., & Adjei, A. A. (2014) · Progress in tumor research · doi:10.1159/000355895 · Cited by 9
Advances in prostate cancer research models: From transgenic mice to tumor xenografting models
Huang, Y., Cheng, C., Zhang, C., Zhang, Y., Chen, M., Strand, D. W., & Jiang, M. (2016) · Asian journal of urology · doi:10.1016/j.ajur.2016.02.004 · Cited by 9
Towards Best Practice in Establishing Patient-Derived Xenografts
Risbridger, G. P., & Lawrence, M. G. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-55825-7_2 · Cited by 9
Napolitano, S., Martini, G., Martinelli, E., Corte, C. M. D., Morgillo, F., Belli, V., Cardone, C., Matrone, N., Ciardiello, F., & Troiani, T. (2017) · Oncotarget · doi:10.18632/oncotarget.19797 · Cited by 9
Kajitani, T., Makiyama, A., Arita, S., Shimokawa, H., Oda, H., Shirakawa, T., Baba, E., & Esaki, T. (2017) · Anticancer Research · doi:10.21873/anticanres.12101 · Cited by 10
Kanat, Ö., Ertaş, H., & Caner, B. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i11.418 · Cited by 10
Methods and resources to access mutation-dependent effects on cancer drug treatment
Yao, H., Liang, Q., Qian, X., Wang, J., Sham, P. C., & Li, M. J. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bbz109 · Cited by 9
Application of trastuzumab emtansine in HER‐2–positive and KRAS/BRAF‐mutated colon cancer cells
Chung, Y., Chiu, H., Wei, W., Chang, K., & Chao, W. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13255 · Cited by 10
Kamitani, N., Nakamae, I., Yoneda‐Kato, N., Kato, J., & Sho, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-26863-y · Cited by 9
Internò, V., Tucci, M., Pezzicoli, G., Silvestris, F., Porta, C., & Mannavola, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581130 · Cited by 9
Boosting human immunology: harnessing the potential of immune organoids
Moll, M., & Baumjohann, D. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00193-8 · Cited by 8
Human epidermal growth factor receptor 2-positive digestive tumors
Wagner, D., Özdemir, B. C., & Rüschoff, J. (2019) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000544 · Cited by 8
CONNECTOR, fitting and clustering of longitudinal data to reveal a new risk stratification system
Pernice, S., Sirovich, R., Grassi, E., Viviani, M., Ferri, M., Sassi, F. P., Alessandrì, L., Tortarolo, D., Calogero, R., Trusolino, L., et al. (2023) · Bioinformatics · doi:10.1093/bioinformatics/btad201 · Cited by 9
Self-citationWahoski, C. C., & Singh, B. (2024) · Cancers · doi:10.3390/cancers16132472 · Cited by 10
Valentini, A. M., Cavalcanti, E., Maggio, M. D., & Caruso, M. L. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000475 · Cited by 8
Clinical Response to T-DM1 in HER2-Amplified, KRAS-Mutated Metastatic Colorectal Cancer.
Sandhu, J. S., Wang, C., & Fakih, M. (2020) · PubMed · doi:10.6004/jnccn.2019.7371 · Cited by 8
Current research developments of patient‑derived tumour xenograft models (Review)
Yin, Z., Maswikiti, E. P., Liu, Q., Bai, Y., Li, X., Qi, W., Le, L., Ma, Y., & Chen, H. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10640 · Cited by 8
Lin, P.-H., Tseng, C.-L., Cheng, Y.-C., Ho, C.-H., Chen, S. C., Wang, Y., Liu, E. W., Issafras, H., & Jiang, W. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1988072 · Cited by 7
Liu, Y., Li, W., Lü, Z., Lu, M. S., Zhou, J., Peng, Z., Zhang, X., Wang, X., Shen, L., & Li, J. (2022) · BMC Cancer · doi:10.1186/s12885-022-09447-x · Cited by 8
Review of the Role of HER2/neu in Colorectal Carcinomas
Achalla, L. S. V., Shinde, R. K., Jogdand, S., & Vodithala, S. (2022) · Cureus · doi:10.7759/cureus.25409 · Cited by 8
Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models
Neia, C. P., Cavalloni, G., Soster, M., Gammaitoni, L., Marchiò, S., Sassi, F. P., Trusolino, L., Bertotti, A., Médico, E., Capussotti, L., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-918 · Cited by 8
Self-citationPillai, S. P. S., & Uthamanthil, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804010-2.00001-1 · Cited by 8
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
Battaglin, F., Puccini, A., Naseem, M., Schirripa, M., Berger, M. D., Tokunaga, R., McSkane, M., Khoukaz, T., Soni, S., Zhang, W., et al. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.04 · Cited by 8
The Clinical Landscape of Circulating Tumor DNA in Gastrointestinal Malignancies
Sawada, K., Kotani, D., & Bando, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00263 · Cited by 8
Current and future therapies for targeting HER2 mutations in gastrointestinal cancer
Dika, I. E., & Ilson, D. H. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1510324 · Cited by 8
One tool to find them all: a case of data integration and querying in a distributed LIMS platform
Grand, A., Geda, E., Mignone, A., Bertotti, A., & Fiori, A. (2019) · Database · doi:10.1093/database/baz004 · Cited by 8
Self-citationFirst‐line therapy for metastatic colorectal cancer: Current perspectives and future directions
Burge, M., Price, T. J., & Karapetis, C. S. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13119 · Cited by 8
Nakamura, Y., Sawada, K., Fujii, S., & Yoshino, T. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000530 · Cited by 8
Prete, A. A., Angerilli, V., Bergamo, F., Vettore, V., Toni, C. D., Intini, R., Cerma, K., Ricagno, G., Cerantola, R., Perissinotto, E., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-023-02569-4 · Cited by 8
Unsupervised Gene Identification in Colorectal Cancer
Barbiero, P., Bertotti, A., Ciravegna, G., Cirrincione, G., Pasero, E. G. A., & Piccolo, E. (2018) · Smart innovation, systems and technologies · doi:10.1007/978-3-319-95095-2_21 · Cited by 7
Self-citationEstablishment and Identification of Patient-Derived Xenograft Model for Oral Squamous Cell Carcinoma
He, F., Zhou, X., Huang, G., Jiang, Q., Wan, L., & Qiu, J. (2022) · Journal of Oncology · doi:10.1155/2022/3135470 · Cited by 7
Fakih, M. (2013) · Future Oncology · doi:10.2217/fon.12.204 · Cited by 6
Neural Biclustering in Gene Expression Analysis
Barbiero, P., Ciravegna, G., Piccolo, E., Cirrincione, G., Cirrincione, M., & Bertotti, A. (2017) · International Conference on Computational Science and Computational Intelligence (CSCI) · doi:10.1109/csci.2017.361 · Cited by 7
Self-citationFontana, E., Nyamundanda, G., Cunningham, D., Tu, D., Cheang, M. C. U., Jonker, D. J., Siu, L. L., Sclafani, F., Eason, K., Ragulan, C., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00050 · Cited by 7
Self-citationCandiello, E., Reato, G., Verginelli, F., Gambardella, G., D′Ambrosio, A., Calandra, N., Orzan, F., Iuliano, A., Albano, R., Sassi, F. P., et al. (2023) · Molecular Oncology · doi:10.1002/1878-0261.13408 · Cited by 7
Self-citationCao, C., Lu, X., Guo, X., Zhao, H., & Gao, Y. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113538 · Cited by 7
Ree, A. H., Kristensen, A. T., Sælen, M. G., de Wijn, R., Edvardsen, H., Jovanovic, J., Abrahamsen, T. W., Dueland, S., & Flatmark, K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050806 · Cited by 7
Sobani, Z. A., Sawant, A. S., Jafri, M., Correa, A. K., & Şahin, İ. H. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i5.340 · Cited by 7
Haslem, D. S., Ji, H. P., Ford, J. M., & Nadauld, L. D. (2017) · JCO Precision Oncology · doi:10.1200/po.16.00055 · Cited by 7
Patient-Derived Xenograft Models in Breast Cancer Research
Na, D., & Moon, H. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9620-6_14 · Cited by 7
Bonjoch, L., Mur, P., Arnau‐Collell, C., Vargas‐Parra, G., Shamloo, B., Franch‐Expósito, S., Pineda, M., Capellá, G., Erman, B., & Castellvı́-Bel, S. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.03.004 · Cited by 9
Aung, K. L., Stockley, T. L., Serra, S., Kamel‐Reid, S., Bedard, P. L., & Siu, L. L. (2016) · Molecular Case Studies · doi:10.1101/mcs.a001016 · Cited by 7
Scalable integration of multiomic single-cell data using generative adversarial networks
Giansanti, V., Giannese, F., Botrugno, O. A., Gandolfi, G., Balestrieri, C., Antoniotti, M., Tonon, G., & Cittaro, D. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae300 · Cited by 6
Gonzalez, N. S., Marchese, P. V., Baraibar, I., Ros, J., Salvà, F., Rodrı́guez, M., Salvà, C., Vaghi, C., Alcaráz, A., García, A., et al. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2349287 · Cited by 6
Mouse colorectal cancer organoids: Lessons from syngeneic and orthotopic transplantation systems
Muta, Y., & Nakanishi, Y. (2025) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2025.151478 · Cited by 6
Jung, B.-Y., Hong, S., Kim, S. C., & Hwang, C. (2018) · Tissue Engineering and Regenerative Medicine · doi:10.1007/s13770-018-0113-2 · Cited by 6
Tailoring antiHer2 treatment strategies in breast cancer and beyond
Fedele, P., Sanna, V., Santoro, A. N., Iaia, M. L., & Fancellu, A. (2022) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2022.100892 · Cited by 8
Cibler HER2 dans le cancer colorectal
Spitzer, E., Cervera, P., André, T., & Cohen, R. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.01.013 · Cited by 7
Evolution of Tumor Model: From Animal Model of Tumor to Tumor Model in Animal
Dey, N., Sun, Y., Leyland-Jones, B., & De, P. K. R. (2013) · Journal of Cancer Therapy · doi:10.4236/jct.2013.49168 · Cited by 6
Feng, T., Golji, J., Li, A., Zhang, X., Ruddy, D. A., Rakiec, D. P., Geyer, F. C., Gu, J., Gao, H., Williams, J. A., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0028 · Cited by 6
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model
Luo, M., He, Y., Xie, B., Li, S., Gan, F., Zhang, S., & Luo, P. (2021) · Pediatric Surgery International · doi:10.1007/s00383-021-04895-1 · Cited by 6
Wang, C., & Fakih, M. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7023 · Cited by 7
Ongoing and evolving clinical trials enhancing future colorectal cancer treatment strategies
Ros, J., Gonzalez, N. S., Salvà, F., Baraibar, I., Alonso, G., Tabernero, J. M., & Élez, E. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2040016 · Cited by 6
Heitzer, E., Mohan, S., Ulz, P., Lafer, I., Auer, M., Lax, S., Höefler, G., Bauernhofer, T., Geigl, J. B., & Speicher, M. R. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)50357-7 · Cited by 6
Prospects and challenges of ovarian cancer organoids in chemotherapy research (Review)
Zhang, W., Ding, Y., He, H., Chen, K., Zeng, Q., Cao, X., Xiang, Y., & Zeng, H. (2025) · Oncology Letters · doi:10.3892/ol.2025.14944 · Cited by 6
Avolio, M., Leto, S. M., Sassi, F. P., Lupo, B., Grassi, E., Catalano, I., Zanella, E. R., Vurchio, V., Cottino, F., Tsantoulis, P. K., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0556 · Cited by 6
Self-citationDinić, J., Stojanov, S. J., Dragoj, M., Grozdanić, M., Podolski-Renić, A., & Pešić, M. (2024) · Life · doi:10.3390/life14091142 · Cited by 6
Hoyek, C., Zheng-Lin, B., Jones, J. C., & Bekaii‐Saab, T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472411 · Cited by 5
Lu, Y., Lei, X., Xu, Y., Li, Y., Wang, R., Wang, S., Wu, A., & Qin, C. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101634 · Cited by 5
Sur, D. G., Havasi, A. D., Gorzo, A., & Burz, C. C. (2020) · Current Drug Targets · doi:10.2174/1389450121666200727121011 · Cited by 5
Gasparini, P., Casanova, M., Centonze, G., Borzi, C., Bergamaschi, L., Collini, P., Testi, A., Chiaravalli, S., Massimino, M., Sozzi, G., et al. (2022) · Tumori Journal · doi:10.1177/03008916221110266 · Cited by 5
Metadata
- Authors
- Bertotti, A., Migliardi, G., Galimi, F., Sassi, F., Torti, D., Isella, C., Corà, D., Di Nicolantonio, F., Buscarino, M., Petti, C., Ribero, D., Russolillo, N., Muratore, A., Massucco, P., Pisacane, A., Molinaro, L., Valtorta, E., Sartore-Bianchi, A., Risio, M., Capussotti, L., Gambacorta, M., Siena, S., Medico, E., Sapino, A., Marsoni, S., Comoglio, P. M., Bardelli, A., & Trusolino, L.
- Affiliations
- IFOM (IT)
- Authors' Affiliations: 1Laboratory of Molecular Pharmacology, 2Laboratory of Oncogenomics, 3Laboratory of Systems Biology, 4Laboratory of Molecular Genetics, 5Division of Surgical Oncology, 6Unit of Pathology, 7Clinical Coordination Unit, and 8Molecular Clinical Oncology, Institute for Cancer Research and Treatment, Torino; Departments of 9Oncological Sciences and 10Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; 11Department of Surgery, Mauriziano Umberto I Hospital, Torino; 12FIRC Institute of Molecular Oncology, Milano; 13Division of Pathology, 14Falck Division of Medical Oncology, Ospedale Niguarda Ca' Granda, Milano; and 15Southern Europe New Drug Organization Foundation, Milano, Italy
- ORCID
- Venue
- Cancer Discovery
- Published
- 2011-11-01
- Volume
- 1
- Issue
- 6
- Pages
- 508-523
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W1987443121
- Cited by
- 939
- References
- 56
- Citations by year
- 2026: 24 · 2025: 42 · 2024: 46 · 2023: 79 · 2022: 72 · 2021: 74 · 2020: 71 · 2019: 86 · 2018: 86 · 2017: 90 · 2016: 71 · 2015: 62 · 2014: 60 · 2013: 48 · 2012: 23
- FWCI
- 21.44
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Funders
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Associazione Italiana per la Ricerca sul Cancro
- Regione Piemonte
- Genentech
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- patient-derived xenografts, metastatic colorectal cancer, cetuximab resistance, HER2 amplification, anti-EGFR therapy, predictive biomarkers, combination therapy, KRAS wild-type, BRAF wild-type, treatment resistance, tumor heterogeneity
- MeSH terms
- Cetuximab, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Prospective Studies, Biomarkers, Tumor, Colorectal Neoplasms, ras Proteins, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Mice, Molecular Targeted Therapy, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
